We have a core management team of executives and scientists, with a total of seventy years of pharmaceutical, biotechnology, scientific and financial management experience.
For information regarding CytoGenix's ethics policy, guidelines, and governance charter, please download any of the PDFs below:
Code of Business Conduct and Ethics (2008)
Corporate Governance Committee Charter (2008)
Corporate Governance Guidelines (2008)
Management Team
Lex M. Cowsert, PhD – President and Chief Executive Officer
Dr. Cowsert has over 19 years of experience in drug discovery and development. Currently he is a co-founder and serves as the Chief Scientific Officer of BellairePharma, inc., founded in 2007 and is a co-founder and CSO of HoustonPharma, Inc., founded in 2005. From 2002 to 2004 Dr. Cowsert served as CSO of Automated Cell, Inc., an imaging-based technology company engaged in drug discovery and development. From 2000 to 2002 he was Vice President of Functional Genomics for VistaGen Therapeutics, Inc. a stem cell-based technology company engaged in drug discovery and development. From 1989 until 2000 Dr. Cowsert held a series of positions of increasing responsibility in the scientific and clinical development programs at Isis Pharmaceuticals, Inc. Dr. Cowsert is sole inventor on 19 issued US Patents and a named inventor on 119 issued U.S. Patents. Dr. Cowsert received his BS in biology from the
University of Florida and earned his PhD in Molecular Biology from Georgetown University. Dr. Cowsert completed his post-doctoral work at the National Cancer Institute where successfully competed for and was awarded an NCI Intramural Research Training Award (1987), National Research Service Award (1988) and an NCI Biotechnology Training Fellowship (1989). Dr. Cowsert has a broad range of experience and expertise in both entrepreneurial and public company settings including: technology development; drug discovery and development; regulatory reports; FDA interactions; venture capital and private equity; US and foreign patent applications; negotiated and managed industrial and academic collaborations; identified, negotiated and in-licensed technologies for commercial development. Successfully applied for and managed SBIR and RO1 government grants.
Randy Moseley – Principal Financial Officer and Chairman
Mr. Moseley joined the CytoGenix Board of Directors in August 2008 and currently serves as Principal Financial Officer for the Company. He con-currently serves as Vice President and Chief Financial Officer of Utilicraft Aerospace Industries, Inc. and as Executive Vice President and Chief Financial Officer of Urban America Television Network Corporation (UATV). In addition, Mr. Moseley has served as Chief Financial Officer for American Independent Network, Inc, Furia Organization, Inc, and Big Sky Industries, Inc. Mr. Moseley is a co-founder of Capital Equity Partners, LLC and has worked with Fronthaul, Inc, Tensor Information Systems, Jerry Lancaster and Asscts, and Pecan Valley Nut Company. Mr. Moseley received his CPA certification in 1972 and graduated with a BBA in accounting from Southern Methodist University in 1970.
Cindee Ewell, PhD, JD – Vice President of Legal Affairs and Secretary
Dr. Ewell joined the CytoGenix team in 2004 and is currently the Company's resident corporate and patent counsel. She received her law degree from South Texas College of Law, her bachelor's degree in Microbiology from Cornell University, and her doctorate in Biochemistry and Molecular Biology from the University of Texas Health Science Center at Houston. She is a registered patent attorney and is licensed to practice law in the State of Texas. Her experience includes nearly eight years of research at Baylor College of Medicine, four years of law firm patent experience and her current tenure with the Company with various corporate law fields. She entered the legal field in 1999 as a biotechnology technical advisor in the field of intellectual property focusing on freedom to operate analyses and patent prosecution. She has established herself as a patent and corporate attorney with a specialty in biotechnology.
Greg S. Taylor, CPA – Vice President of Finance and Administration and CFO
Mr. Taylor has almost 20 years of investment banking, venture capital, corporate and entrepreneurial experience and has completed over $2BB in transactions. He has also served in management positions as both a CEO and CFO. He was most recently Managing Director of Monterey Capital Partners, a private equity investment firm, for over ten years. Previously, he served as a Vice President with the investment banking division of Sumitomo Trust and Banking and with Bunker Hill Associates, a merchant-banking firm. Mr. Taylor began his career with Ernst and Whinney, a big eight accounting firm in Houston, Texas as a Certified Public Accountant. Mr. Taylor has served on the board of directors of several private companies and charitable organizations. He has a Bachelor of Business Administration in Accounting and Finance from Baylor University and also a Masters of Taxation from Baylor University.
Randy Moseley is Chairman to the Board in addition to Principal Financial Officer.
Lex Cowsert, PhD is a Director to the Board in addition to President and Chief Executive Officer.
Cy A. Stein, MD PhD is currently Professor of Medicine, Urology and Molecular Pharmacology in the Oncology Department of Albert Einstein College of Medicine, New York. In addition to his clinical (Director of Medical Genitourinary Oncology, Montefiore Medical Center) and faculty activities, he is co-editor-in-chief of Oligonucleotides, sits on six editorial advisory boards, including Clinical Cancer Research and Molecular Cancer Therapeutics, serves on eight scientific advisory boards, including Novosom (Halle, DE), ProNai (Kalamazoo, MI), SR Pharma (Berlin, DE) and Gentium (Como, IT) and is an ad hoc reviewer for over 20 peer reviewed journals. He has authored 115 peer reviewed journal articles. He has written 77 book chapters, reviews and editorials, and he holds eleven patents issued and one patent pending. He attended Brown University (BA), Stanford University (PhD in Organic Chemistry), Albert Einstein College of Medicine (MD), and New York Hospital-Cornell Medical Center (Internship and Residency in Internal Medicine). Dr Stein was a Clinical Associate and Senior Staff Fellow at The National Cancer Institute, Bethesda, Maryland.
John J. Rossi, PhD is Chairman and a Professor in the Division of Molecular Biology at the Beckman Research Institute of City of Hope. He first joined the City of Hope (COH) faculty in 1980 as an assistant research scientist in the Department of Molecular Genetics. He has been affiliated with multiple divisions and research centers in various leadership capacities within COH and has received multiple acclaimed awards. In 1993, COH bestowed its highest honor upon him by naming him to its Gallery of Medical and Scientific Achievement for his pioneering work at the molecular level in the battle against AIDS and other major diseases. Dr. Rossi is a world-renowned expert in ribozymes (molecular scissors). Dr. Rossi's major contributions to science have been related to understanding the processing and metabolism of RNA inside the cell. One of his most notable projects has involved the use of ribozymes in AIDS research and was involved with the first efforts to use ribozymes in the treatment of HIV. He is an inventor on multiple patents and an author of more than 120 scientific papers. Dr. Rossi received his bachelor's degree from the University of New Hampshire and his doctorate from the University of Connecticut, and worked as a postdoctoral fellow for four years at Brown University in Providence, Rhode Island.
Scientific Advisory Board
Our Scientific Advisory Board is comprised of leading scientists and clinician authorities in the fields of dermatology, cancer research and gene therapy.
Cy A. Stein, MD PhD
Dr. Stein is currently Professor of Medicine, Urology and Molecular Pharmacology in the Oncology Department of Albert Einstein College of Medicine, New York. In addition to his clinical (Director of Medical Genitourinary Oncology, Montefiore Medical Center) and faculty activities, he is co-editor-in-chief of Oligonucleotides, sits on six editorial advisory boards, including Clinical Cancer Research and Molecular Cancer Therapeutics, serves on eight scientific advisory boards, including Novosom (Halle, DE), ProNai (Kalamazoo, MI), SR Pharma (Berlin, DE) and Gentium (Como, IT) and is an ad hoc reviewer for over 20 peer reviewed journals. He has authored 115 peer reviewed journal articles. He has written 77 book chapters, reviews and editorials, and he holds eleven patents issued and one patent pending. He attended Brown University (BA), Stanford University (PhD in Organic Chemistry), Albert Einstein College of Medicine (MD), and New York Hospital-Cornell Medical Center (Internship and Residency in Internal Medicine). Dr. Stein was a Clinical Associate and Senior Staff Fellow at The National Cancer Institute, Bethesda, Maryland.
Peter Glazer, MD PhD
Dr. Glazer holds academic degrees from Harvard (BA), Oxford (MS), and Yale (Ph.D.) and a Medical Degree from Yale University School of Medicine where he is an Associate Professor of Therapeutic Radiology and Genetics.His research interests include gene targeting and gene therapy, genetic instability in cancer, mutagenesis, and DNA repair.
Madeleine Duvic, MD
Dr. Duvic is a Professor of Medicine Chief, Section of Dermatology, and Associate Medical Director of the Melanoma Skin Center at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Duvic received her B.A. from Rice University, magna cum laude, as a National Merit Scholar and her M.D. from Duke University Medical School.
Samuel Kaplan, PhD
Dr. Kaplan is Professor and Chairman of the Department of Microbiology of the University of Texas, Houston Medical School. He is Chairman of the publications board of the American Society of Microbiology, the recipient of twelve honorary awards, has authored over 200 scientific papers. He earned his bachelor's degree from Cornell University, his masters from Yale and his doctorate from the University of California San Diego. He trained for two years at Cambridge University and joined the faculty of the University of Illinois-Urbana in 1967 where he later became the director of the Biotechnology Center. In 1989, he took the position of Chairman of the Department of Microbiology at the University of Texas Houston Medical School.
